Bayer to Acquire Partner, Algeta (Bloomberg)
German drug-maker Bayer AG is negotiating to buy out partner, Algeta SA. The Norway-based drug company currently shares control of its prostate cancer medicine with Germany’s Bayer. Under the proposed deal, Bayer would take full control of the drug, along with a pipeline of experimental radiation therapies. Bayer has offered 14.8 billion kroner (about $2.42 billion) for Algeta, a price which would value Algeta at a 27 percent premium to yesterday’s close. Looking ahead, it’s unclear what effect the acquisition will have on Bayer’s bottom line.
This content is for paid subscribers only. To gain access subscribe to one of our…
It is hard to find a seasoned investor who doesn’t believe the stock market is…
No one believes a financial disaster can strike… until it’s too late. That’s bizarre, considering…
The Options Industry Council is a resource used to educate investors about the benefits and…
The put-call parity is the relationship that exists between put and call prices of the…
“It’s not a stock market, it’s a market of stocks.” -- “Maxims of Wall Street,”…